{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:18:39Z","timestamp":1792001919459,"version":"4.4.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-13941-3","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T23:10:35Z","timestamp":1743808235000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217)"],"prefix":"10.1186","volume":"25","author":[{"given":"Jaume","family":"Capdevila","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Pubul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urbano","family":"Anido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Molina-Cerrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Alonso-Gordoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocio","family":"Garcia-Carbonero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"San-Roman-Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belen","family":"Llana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Jimenez-Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Benavent Vi\u00f1uales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Ansquer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Baudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Come","family":"Lepage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maribel","family":"del Olmo-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Carlos","family":"Ruffinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandine","family":"Beron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magalie","family":"Haissaguerre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Deshayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ta\u00efeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Baldari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Sansovini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Cingarlini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelina","family":"Filice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Panzuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"\u00c1lvarez-\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Lousberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Aboubakar Nana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Hernando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejando","family":"Garc\u00eda-\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amparo","family":"Garc\u00eda-Burillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Villacampa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timon","family":"Vandamme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Durand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,4]]},"reference":[{"issue":"4","key":"13941_CR1","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.annonc.2021.01.003","volume":"32","author":"E Baudin","year":"2021","unstructured":"Baudin E, Caplin M, Garcia-Carbonero R, Fazio N, Ferolla P, Filosso PL, et al. Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2606. Ann Oncol Off J Eur Soc Med Oncol. 2021;32(4):439\u201351.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"1","key":"13941_CR2","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12890-018-0678-5","volume":"18","author":"MS Broder","year":"2018","unstructured":"Broder MS, Cai B, Chang E, Neary MP. Incidence and prevalence of neuroendocrine tumors of the lung: analysis of a US commercial insurance claims database. BMC Pulm Med. 2018;18(1):135.","journal-title":"BMC Pulm Med"},{"issue":"8","key":"13941_CR3","first-page":"1975","volume":"49","author":"CM Korse","year":"2013","unstructured":"Korse CM, Taal BG, van Velthuysen MLF, Visser O. Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: experience of two decades of cancer registry. Eur J Cancer Oxf Engl 1990. 2013;49(8):1975\u201383.","journal-title":"Eur J Cancer Oxf Engl 1990"},{"issue":"9","key":"13941_CR4","first-page":"1243","volume":"10","author":"WD Travis","year":"2015","unstructured":"Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2015;10(9):1243\u201360.","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"issue":"9","key":"13941_CR5","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1210\/jc.2014-1560","volume":"99","author":"JM de Laat","year":"2014","unstructured":"de Laat JM, Pieterman CR, van den Broek MF, Twisk JW, Hermus AR, Dekkers OM, et al. Natural course and survival of neuroendocrine tumors of thymus and lung in MEN1 patients. J Clin Endocrinol Metab. 2014;99(9):3325\u201333.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"13941_CR6","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.athoracsur.2016.07.050","volume":"103","author":"JL Sullivan","year":"2017","unstructured":"Sullivan JL, Weksler B. Neuroendocrine tumors of the thymus: analysis of factors affecting survival in 254 patients. Ann Thorac Surg. 2017;103(3):935\u20139.","journal-title":"Ann Thorac Surg"},{"issue":"4","key":"13941_CR7","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1093\/ejcts\/ezt470","volume":"45","author":"N Daddi","year":"2014","unstructured":"Daddi N, Schiavon M, Filosso PL, Cardillo G, Ambrogi MC, De Palma A, et al. Prognostic factors in a multicentre study of 247 atypical pulmonary carcinoids. Eur J Cardio-Thorac Surg Off J Eur Assoc Cardio-Thorac Surg. 2014;45(4):677\u201386.","journal-title":"Eur J Cardio-Thorac Surg Off J Eur Assoc Cardio-Thorac Surg"},{"issue":"2","key":"13941_CR8","first-page":"184","volume":"14","author":"JY Yoon","year":"2019","unstructured":"Yoon JY, Sigel K, Martin J, Jordan R, Beasley MB, Smith C, et al. Evaluation of the prognostic significance of TNM staging guidelines in lung carcinoid tumors. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2019;14(2):184\u201392.","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"issue":"1","key":"13941_CR9","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/ejcts\/ezx037","volume":"52","author":"Y Zhao","year":"2017","unstructured":"Zhao Y, Gu H, Fan L, Han K, Yang J, Zhao H. Comparison of clinical features and survival between thymic carcinoma and thymic carcinoid patients. Eur J Cardio-Thorac Surg Off J Eur Assoc Cardio-Thorac Surg. 2017;52(1):33\u20138.","journal-title":"Eur J Cardio-Thorac Surg Off J Eur Assoc Cardio-Thorac Surg"},{"issue":"Suppl 15","key":"13941_CR10","doi-asserted-by":"publisher","first-page":"S1435","DOI":"10.21037\/jtd.2017.09.83","volume":"9","author":"M Garc\u00eda-Yuste","year":"2017","unstructured":"Garc\u00eda-Yuste M, Matilla JM, Ca\u00f1izares MA, Molins L, Guijarro R. Surgical treatment of low and intermediate grade lung net. J Thorac Dis. 2017;9(Suppl 15):S1435\u201341.","journal-title":"J Thorac Dis"},{"issue":"4","key":"13941_CR11","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1470-2045(17)30110-9","volume":"18","author":"DM Halperin","year":"2017","unstructured":"Halperin DM, Shen C, Dasari A, Xu Y, Chu Y, Zhou S, et al. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol. 2017;18(4):525\u201334.","journal-title":"Lancet Oncol"},{"issue":"1","key":"13941_CR12","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1309\/3PDN-PMT5-EQTM-H0CD","volume":"114","author":"CA Moran","year":"2000","unstructured":"Moran CA, Suster S. Neuroendocrine carcinomas (carcinoid tumor) of the thymus. A clinicopathologic analysis of 80 cases. Am J Clin Pathol. 2000;114(1):100\u201310.","journal-title":"Am J Clin Pathol"},{"issue":"12","key":"13941_CR13","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/S1470-2045(17)30681-2","volume":"18","author":"P Ferolla","year":"2017","unstructured":"Ferolla P, Brizzi MP, Meyer T, Mansoor W, Mazieres J, Do Cao C, et al. Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2017;18(12):1652\u201364.","journal-title":"Lancet Oncol"},{"issue":"7","key":"13941_CR14","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","volume":"31","author":"M Pavel","year":"2020","unstructured":"Pavel M, \u00d6berg K, Falconi M, Krenning EP, Sundin A, Perren A, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. 2020;31(7):844\u201360.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"75","key":"13941_CR15","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ejca.2016.11.034","volume":"1","author":"I Sullivan","year":"2017","unstructured":"Sullivan I, Le Teuff G, Guigay J, Caramella C, Berdelou A, Leboulleux S, et al. Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoids. Eur J Cancer. 2017;1(75):259\u201367.","journal-title":"Eur J Cancer"},{"issue":"4","key":"13941_CR16","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.cllc.2016.11.004","volume":"18","author":"A Bongiovanni","year":"2017","unstructured":"Bongiovanni A, Recine F, Riva N, Foca F, Liverani C, Mercatali L, et al. Outcome analysis of first-line somatostatin analog treatment in metastatic pulmonary neuroendocrine tumors and prognostic significance of 18FDG-PET\/CT. Clin Lung Cancer. 2017;18(4):415\u201320.","journal-title":"Clin Lung Cancer"},{"issue":"6","key":"13941_CR17","first-page":"993","volume":"14","author":"P Robelin","year":"2019","unstructured":"Robelin P, Hadoux J, Forestier J, Planchard D, Hervieu V, Berdelou A, et al. Characterization, prognosis, and treatment of patients with metastatic lung carcinoid tumors. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2019;14(6):993\u20131002.","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"issue":"6","key":"13941_CR18","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1159\/000444087","volume":"103","author":"F Spada","year":"2016","unstructured":"Spada F, Antonuzzo L, Marconcini R, Radice D, Antonuzzo A, Ricci S, et al. Oxaliplatin-based chemotherapy in advanced neuroendocrine tumors: clinical outcomes and preliminary correlation with biological factors. Neuroendocrinology. 2016;103(6):806\u201314.","journal-title":"Neuroendocrinology"},{"issue":"1","key":"13941_CR19","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1634\/theoncologist.2019-0361","volume":"25","author":"T Al-Toubah","year":"2020","unstructured":"Al-Toubah T, Morse B, Strosberg J. Capecitabine and temozolomide in advanced lung neuroendocrine neoplasms. Oncologist. 2020;25(1):e48-52.","journal-title":"Oncologist"},{"issue":"10022","key":"13941_CR20","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","volume":"387","author":"JC Yao","year":"2016","unstructured":"Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016;387(10022):968\u201377.","journal-title":"Lancet"},{"issue":"1","key":"13941_CR21","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/cas.13427","volume":"109","author":"N Fazio","year":"2018","unstructured":"Fazio N, Buzzoni R, Delle Fave G, Tesselaar ME, Wolin E, Van Cutsem E, et al. Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis. Cancer Sci. 2018;109(1):174\u201381.","journal-title":"Cancer Sci"},{"issue":"9","key":"13941_CR22","doi-asserted-by":"publisher","first-page":"e230337","DOI":"10.1530\/ERC-23-0337","volume":"31","author":"E Baudin","year":"2024","unstructured":"Baudin E, Capdevila J, H\u00f6rsch D, Singh S, Caplin ME, Wolin EM, et al. Treatment of advanced BP-NETS with lanreotide autogel\/depot vs placebo: the phase III SPINET study. Endocr Relat Cancer. 2024;31(9):e230337.","journal-title":"Endocr Relat Cancer"},{"key":"13941_CR23","doi-asserted-by":"publisher","first-page":"viii478","DOI":"10.1093\/annonc\/mdy293.028","volume":"29","author":"ME Pavel","year":"2018","unstructured":"Pavel ME, Rinke A, Baum RP. COMPETE trial: Peptide receptor radionuclide therapy (PRRT) with 177Lu-edotreotide vs. everolimus in progressive GEP-NET. Ann Oncol. 2018;29:viii478.","journal-title":"Ann Oncol."},{"issue":"33","key":"13941_CR24","doi-asserted-by":"publisher","first-page":"S960","DOI":"10.1016\/j.annonc.2022.07.1028","volume":"1","author":"TR Halfdanarson","year":"2022","unstructured":"Halfdanarson TR, Halperin D, Reidy-Lagunes D, Kong G, Mailman J, Herrmann K, et al. 902TiP COMPOSE: pivotal phase III trial to compare 177Lu-edotreotide with best standard of care for well-differentiated aggressive grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumours. Ann Oncol. 2022;1(33):S960.","journal-title":"Ann Oncol"},{"issue":"4","key":"13941_CR25","doi-asserted-by":"publisher","first-page":"501","DOI":"10.7150\/thno.13702","volume":"6","author":"RP Baum","year":"2016","unstructured":"Baum RP, Kluge AW, Kulkarni H, Schorr-Neufing U, Niepsch K, Bitterlich N, et al. [177Lu-DOTA]0-D-Phe1-Tyr3-Octreotide (177Lu-DOTATOC) for peptide receptor radiotherapy in patients with advanced neuroendocrine tumours: a phase-II study. Theranostics. 2016;6(4):501\u201310.","journal-title":"Theranostics"},{"issue":"2","key":"13941_CR26","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125\u201335.","journal-title":"N Engl J Med"},{"issue":"12","key":"13941_CR27","first-page":"1712","volume":"62","author":"JR Strosberg","year":"2021","unstructured":"Strosberg JR, Srirajaskanthan R, El-Haddad G, Wolin EM, Chasen BR, Kulke MH, et al. Symptom diaries of patients with midgut neuroendocrine tumors treated with 177Lu-DOTATATE. J Nucl Med Off Publ Soc Nucl Med. 2021;62(12):1712\u20138.","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"issue":"3","key":"13941_CR28","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1159\/000475526","volume":"105","author":"RJ Hicks","year":"2017","unstructured":"Hicks RJ, Kwekkeboom DJ, Krenning E, Bodei L, Grozinsky-Glasberg S, Arnold R, et al. ENETS consensus guidelines for the standards of care in neuroendocrine neoplasia: peptide receptor radionuclide therapy with radiolabeled somatostatin analogues. Neuroendocrinology. 2017;105(3):295\u2013309.","journal-title":"Neuroendocrinology"},{"issue":"6","key":"13941_CR29","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1007\/s00259-015-3262-8","volume":"43","author":"A Ianniello","year":"2016","unstructured":"Ianniello A, Sansovini M, Severi S, Nicolini S, Grana CM, Massri K, et al. Peptide receptor radionuclide therapy with (177)Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and (18)F-FDG PET. Eur J Nucl Med Mol Imaging. 2016;43(6):1040\u20136.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"16","key":"13941_CR30","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","volume":"23","author":"T Brabander","year":"2017","unstructured":"Brabander T, van der Zwan WA, Teunissen JJM, Kam BLR, Feelders RA, de Herder WW, et al. Long-term efficacy, survival, and safety of [177Lu-DOTA0, Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin Cancer Res Off J Am Assoc Cancer Res. 2017;23(16):4617\u201324.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"17","key":"13941_CR31","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1200\/JCO.2010.33.7873","volume":"29","author":"A Imhof","year":"2011","unstructured":"Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(17):2416\u201323.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"2","key":"13941_CR32","first-page":"74","volume":"7","author":"A Sabet","year":"2017","unstructured":"Sabet A, Haug AR, Eiden C, Auernhammer CJ, Simon B, Bartenstein P, et al. Efficacy of peptide receptor radionuclide therapy with 177Lu-octreotate in metastatic pulmonary neuroendocrine tumors: a dual-centre analysis. Am J Nucl Med Mol Imaging. 2017;7(2):74\u201383.","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"13941_CR33","unstructured":"Study Details | Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors | ClinicalTrials.gov. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04665739?term=typical%20carcinoid%20dotatate&rank=4. Cited 2024 Sep 9."},{"key":"13941_CR34","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/978-3-031-33533-4_34","volume-title":"Beyond Becquerel and biology to precision radiomolecular oncology: Festschrift in HONOr of Richard P Baum","author":"MV Todorovi\u0107-Tirnani\u0107","year":"2024","unstructured":"Todorovi\u0107-Tirnani\u0107 MV, van Echteld CJA, Gaji\u0107 MM, Baum RP. Uptake of 68Ga-DOTATATE and 68Ga-DOTATOC in primary neuroendocrine tumors, metastases, and normal liver tissue: is there a significant difference? In: Prasad V, editor. Beyond Becquerel and biology to precision radiomolecular oncology: Festschrift in HONOr of Richard P Baum. Cham: Springer International Publishing; 2024. p. 337\u201348. https:\/\/doi.org\/10.1007\/978-3-031-33533-4_34. Available from: Cited 2024 Oct 16."},{"issue":"10446","key":"13941_CR35","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","volume":"403","author":"S Singh","year":"2024","unstructured":"Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, et al. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2\u20133, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024;403(10446):2807\u201317.","journal-title":"Lancet"},{"issue":"9","key":"13941_CR36","doi-asserted-by":"publisher","first-page":"e3665","DOI":"10.1210\/clinem\/dgab289","volume":"106","author":"WT Zandee","year":"2021","unstructured":"Zandee WT, Brabander T, Bla\u017eevi\u0107 A, Minczeles NS, Feelders RA, de Herder WW, et al. Peptide receptor radionuclide therapy with 177Lu-DOTATATE for symptomatic control of refractory carcinoid syndrome. J Clin Endocrinol Metab. 2021;106(9):e3665\u201372.","journal-title":"J Clin Endocrinol Metab"}],"updated-by":[{"DOI":"10.1186\/s12885-026-16297-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000}}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13941-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-13941-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13941-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T13:58:21Z","timestamp":1781359101000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-025-13941-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,4]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13941"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-13941-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,4]]},"assertion":[{"value":"28 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article has been updated: Competing interest has been updated.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12885-026-16297-4","URL":"https:\/\/doi.org\/10.1186\/s12885-026-16297-4","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study is being conducted in accordance with the principles of the Declaration of Helsinki, the International Council for Harmonisation Guidelines for Good Clinical Practice and the local regulations. The study protocol was approved by the IEC of Hospital Universitari Vall D'Hebron on June 19\n                      th\n                      , 2023 (Ref: 2023\/578) and the competent authorities of the European member states concerned (Spain: July 14\n                      th\n                      , 2023, France: October 10\n                      th\n                      , 2023, Italy: November 8\n                      th\n                      , 2023). All patients are providing written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RGC has received honoraria for speaker engagements, advisory roles or funding for continuous medical education from: AAA-Novartis, Advanz Pharma, Astellas, Bayer, BMS, Boehringer, Esteve, GSK, Hutchmed, Ipsen, ITM, MSD, PharmaMar, Pierre Fabre, Sanofi, Servier, Takeda. PJF has received honoraria for speaker engagements, advisory roles or funding for continuous medical education from:\u00a0 Astellas, AstraZeneca, Bristol-Myers Squibb (BMS), Esteve, Merck Sharp & Dohme (MSD), Novartis, Nutricia, Pfizer, Rovi, Takeda, Viatris. TW has received honoraria for speaker engagements, advisory roles or funding for continuous medical education from: Novartis, MSD, Esteve, Ipsen, ITM, Terumo, Pierre Fabre, Sanofi, OranoMed, Sirtex.CL has received honoraria for speaker engagements, advisory roles or funding for continuous medical education from: Pierre Fabre, AMGEN, Takeda, Ipsen, AAA. ED has received fees from AAA-Novartis, Janssen and GE. JCR has received honoraria for speaker engagements, advisory roles or funding for continuous medical education from: AMGEN, MSD, AAA. TV has received honoraria for speaker engagements, advisory roles or funding for continuous medical education from from AstraZeneca, Astellas, Bayer, Bristol Myers Squibb, Eisai, Elmedix, Ipsen, MyNeoTx, Nordic Pharma, Novartis, Roche, Sirtex, Servier, Takeda. TV is a senior clinical investigator at the Research Foundation-Flanders (FWO), project number 1803723N. GV has received a speaker\u2019s fee from Pfizer, MSD, GSK and Pierre Fabrer, has held an advisory role with AstraZeneca and received consultant fees from Reveal Genomics. TAG reports Advisory role or speaker &\u00a0 fee from Lilly, Bayer, Johnson & Johnson, Astellas, Eisai, Roche, Ipsen, MSD\u00a0 and Adacap. Research Grant from Johnson & Johnson and IPSEN. DT is a co-founder, stakeholder, and Chief Medical Officer (CMO) of SILON Therapeutics. All the other co-authors confirmed that they had no competing interests to be declared.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"613"}}